Cargando...
Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy
Hexamethylene bisacetamide-inducible protein 1 (HEXIM1) is best known as the inhibitor of positive transcription elongation factor b (P-TEFb) and is recently identified as a novel positive regulator of p53. We previously showed the basic region (BR) of HEXIM1 mediates the binding of HEXIM1 to a nucl...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4868700/ https://ncbi.nlm.nih.gov/pubmed/26734838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6794 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|